D. Boral Capital Cuts GeoVax Labs (NASDAQ:GOVX) Price Target to $6.00

GeoVax Labs (NASDAQ:GOVX) had its price objective reduced by D. Boral Capital from $9.00 to $6.00 in a research report sent to investors on Wednesday,Benzinga reports. D. Boral Capital currently has a buy rating on the stock.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $7.50.

GeoVax Labs Stock Performance

NASDAQ:GOVX opened at $0.39 on Wednesday. GeoVax Labs has a 52-week low of $0.39 and a 52-week high of $3.15. The company has a market cap of $11.64 million, a P/E ratio of -0.20 and a beta of 3.34. The stock’s 50-day simple moving average is $0.56 and its 200 day simple moving average is $0.74.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.07). GeoVax Labs had a negative return on equity of 408.80% and a negative net margin of 403.88%. As a group, equities analysts predict that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

A number of institutional investors have recently modified their holdings of the business. Armistice Capital LLC acquired a new position in shares of GeoVax Labs in the third quarter valued at about $253,000. Sabby Management LLC bought a new stake in GeoVax Labs in the 3rd quarter valued at about $313,000. Finally, Jane Street Group LLC bought a new stake in GeoVax Labs in the 1st quarter valued at about $27,000. Institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.